Umer Raffat

Stock Analyst at Evercore ISI Group

(1.31)
# 3,267
Out of 4,784 analysts
21
Total ratings
50%
Success rate
-8.61%
Average return

Stocks Rated by Umer Raffat

Metsera
Feb 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $28.00
Upside: -
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $17.94
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $3.66
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.24
Upside: -
RAPT Therapeutics
Feb 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.22
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $33.21
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $14.59
Upside: -
Teva Pharmaceutical Industries
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $15.08
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $6.60
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $14.66
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $35.06
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $14.51
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $2.91
Upside: -
Initiates: Outperform
Price Target: $48
Current: $0.75
Upside: +6,275.35%
Upgrades: Outperform
Price Target: n/a
Current: $306.95
Upside: -
Initiates: Outperform
Price Target: $48
Current: $6.11
Upside: +685.60%
Initiates: Buy
Price Target: n/a
Current: $122.92
Upside: -